Giorgio Walter Canonica

List of Publications by Year
in descending order

465 papers	25,084 citations	8181 76 h-index	10734 138 g-index
476 all docs	476 docs citations	476 times ranked	14807 citing authors

#	Article	IF	Citations
1	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. Journal of Allergy and Clinical Immunology, 2010, 126, 466-476.	2.9	1,322
2	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelinesâ€”2016 revision. Journal of Allergy and Clinical Immunology, 2017, 140, 950-958.	2.9	1,199
3	Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet, The, 2019, 394, 1638-1650.	13.7	812
4	EAACI/GA²LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1417-1426.	5.7	582
5	EAACI/GAÂ²LEN/EDF/WAO guideline: management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1427-1443.	5.7	502
6	Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organization Journal, 2014, 7, 6.	3.5	395
7	A WAO - ARIA - GAÂ²LEN consensus document on molecular-based allergy diagnostics. World Allergy Organization Journal, 2013, 6, 17.	3.5	352
8	World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. World Allergy Organization Journal, 2015, 8, 4.	3.5	332
9	Allergic rhinitis. Nature Reviews Disease Primers, 2020, 6, 95.	30.5	331
10	Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma. New England Journal of Medicine, 2007, 356, 2040-2052.	27.0	320
11	Subâ€lingual Immunotherapy: World Allergy Organization Position Paper 2009. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1-59.	5.7	316
12	Long-lasting effects of sublingual immunotherapy according to its duration: AÂ15-year prospective study. Journal of Allergy and Clinical Immunology, 2010, 126, 969-975.	2.9	312
13	Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Annals of Allergy, Asthma and Immunology, 2006, 97, 141-148.	1.0	288
14	EAACI/GA²LEN/EDF guideline: management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 321-331.	5.7	278
15	Exerciseâ€induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: Part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA²LEN. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 387-403.	5.7	275
16	Noninjection routes for immunotherapy. Journal of Allergy and Clinical Immunology, 2003, 111, 437-448.	2.9	266
17	Metaanalysis of the Efficacy of Sublingual Immunotherapy in the Treatment of Allergic Asthma in Pediatric Patients, 3 to 18 Years of Age. Chest, 2008, 133, 599-609.	0.8	263
18	Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet, The, 1998, 351, 629-632.	13.7	252

#	Article	IF	Citations
19	IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organization Journal, 2020, 13, 100080.	3.5	245
20	EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2312-2319.	5.7	239
21	Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroidÂuse while maintaining asthma control: AÂrandomized, double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2014, 134, 568-575.e7.	2.9	236
22	Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. Journal of Allergy and Clinical Immunology, 1995, 96, 971-979.	2.9	231
23	EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 316-320.	5.7	221
24	Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Annals of Allergy, Asthma and Immunology, 2008, 101, 206-211.	1.0	213
25	Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. Journal of Allergy and Clinical Immunology, 2007, 120, 164-170.	2.9	210
26	Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitisâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 1999, 104, 425-432.	2.9	206
27	Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. Journal of Allergy and Clinical Immunology, 2004, 114, 838-844.	2.9	199
28	The burden of chronic spontaneous urticaria is substantial: Realâ€world evidence from <scp>ASSURE</scp>â€<scp>CSU</scp>. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 2005-2016.	5.7	197
29	Unmet needs in severe chronic upper airway disease (SCUAD). Journal of Allergy and Clinical Immunology, 2009, 124, 428-433.	2.9	191
30	GA²LEN/EAACI pocket guide for allergenâ€specific immunotherapy for allergic rhinitis and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1525-1530.	5.7	185
31	Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergens. Journal of Allergy and Clinical Immunology, 1995, 96, 580-587.	2.9	166
32	Characterization of Severe Asthma Worldwide. Chest, 2020, 157, 790-804.	0.8	165
33	A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. International Archives of Allergy and Immunology, 2016, 170, 122-131.	2.1	164
34	EAACI Biologicals Guidelinesâ€"Recommendations for severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 14-44.	5.7	156
35	Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trialâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 1999, 104, 964-968.	2.9	155
36	Allergic diseases and asthma. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 39-41.	2.3	154

#	Article	IF	Citations
37	Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders. Current Opinion in Allergy and Clinical Immunology, 2016, 16, 186-200.	2.3	152
38	Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective. World Allergy Organization Journal, 2012, 5, 125-147.	3.5	150
39	The link between allergic rhinitis and asthma: the united airways disease. Expert Review of Clinical Immunology, 2010, 6, 413-423.	3.0	145
40	Grading local side effects of sublingual immunotherapy forÂrespiratory allergy: Speaking the same language. Journal of Allergy and Clinical Immunology, 2013, 132, 93-98.	2.9	144
41	Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years. Annals of Allergy, Asthma and Immunology, 2010, 104, 215-222.	1.0	141
42	2019 ARIA Care pathways for allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2087-2102.	5.7	140
43	Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. Journal of Allergy and Clinical Immunology, 1995, 95, 612-621.	2.9	136
44	Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beingsâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 1997, 100, 122-129.	2.9	134
45	Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 192-197.	5.7	133
46	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	2.9	128
47	World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Prebiotics. World Allergy Organization Journal, 2016, 9, 10.	3.5	123
48	Why do doctors and patients not follow guidelines?. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 228-233.	2.3	119
49	Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 776-781.	3.8	118
50	Type 2 immunity in asthma. World Allergy Organization Journal, 2018, 11, 13.	3.5	116
51	Intranasal corticosteroids in allergic rhinitis in COVIDâ€19 infected patients: An ARIAâ€EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2440-2444.	5.7	114
52	The Severe Asthma Network in Italy: Findings and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1462-1468.	3.8	112
53	Eosinophilic and Noneosinophilic Asthma. Chest, 2021, 160, 814-830.	0.8	109
54	Asthma in the elderly: what we know and what we have yet to know. World Allergy Organization Journal, 2014, 7, 8.	3.5	105

#	Article	IF	Citations
55	Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis. International Archives of Allergy and Immunology, 2013, 161, 369-377.	2.1	104
56	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	2.9	103
57	Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine,the, 2021, 9, 260-274.	10.7	102
58	Sub-Lingual Immunotherapy. World Allergy Organization Journal, 2009, 2, 233-281.	3.5	100
59	Treatment of exerciseâ€induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA²LEN*. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 492-505.	5.7	98
60	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. Clinical and Translational Allergy, 2020, 10, 16.	3.2	97
61	Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. New England Journal of Medicine, 2016, 375, 850-860.	27.0	96
62	How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. Journal of Allergy and Clinical Immunology, 2010, 126, 668-669.	2.9	95
63	Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunology Letters, 2014, 162, 2-10.	2.5	95
64	The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms. Clinical Biochemistry, 2011, 44, 1005-1011.	1.9	91
65	Safety of sublingual immunotherapy with monomeric all_ergoid in adults: multicenter post-marketing surveillance study. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 989-992.	5.7	88
66	Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organization Journal, 2016, 9, 33.	3.5	87
67	Handling of allergen immunotherapy in the COVIDâ€19 pandemic: An ARIAâ€EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1546-1554.	5.7	87
68	SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Annals of Allergy, Asthma and Immunology, 2015, 114, 134-140.e1.	1.0	84
69	Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. European Respiratory Journal, 2020, 56, 2000151.	6.7	84
70	Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Annals of Allergy, Asthma and Immunology, 2009, 102, 22-28.	1.0	82
71	The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clinical and Translational Allergy, 2015, 5, 39.	3.2	82
72	Shadow cost of oral corticosteroids-related adverse events: AÂpharmacoeconomic evaluation applied to real-life data fromÂtheÂSevereÂAsthma Network in Italy (SANI) registry. World Allergy Organization Journal, 2019, 12, 100007.	3.5	82

#	Article	IF	Citations
73	Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: A 3-year randomized controlled study. Journal of Allergy and Clinical Immunology, 2005, 115, 1184-1188.	2.9	81
74	International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. World Allergy Organization Journal, 2017, 10, 14.	3.5	80
75	COVIDâ€19 pandemic: Practical considerations on the organization of an allergy clinicâ€"An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	5.7	79
76	Evidence of adherence to allergen-specific immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 544-548.	2.3	78
77	Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2337-2353.	5.7	78
78	Quantitative assessment of the adherence to sublingual immunotherapy. Journal of Allergy and Clinical Immunology, 2004, 113, 1219-1220.	2.9	77
79	Recommendations for appropriate sublingual immunotherapy clinical trials. Journal of Allergy and Clinical Immunology, 2009, 124, 665-670.	2.9	77
80	Cetirizine Reduces ICAM-I on Epithelial Cells during Nasal Minimal Persistent Inflammation in Asymptomatic Children with Mite-Allergic Asthma. International Archives of Allergy and Immunology, 1996, 109, 272-276.	2.1	76
81	Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from <scp>ASSURE</scp>â€<scp>CSU</scp>. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1724-1734.	5.7	74
82	Minimal clinically important difference for asthma endpoints: an expert consensus report. European Respiratory Review, 2020, 29, 190137.	7.1	72
83	Harmful effect of immunotherapy in children with combined snail and mite allergy. Journal of Allergy and Clinical Immunology, 2002, 109, 627-629.	2.9	71
84	Allergen immunotherapy on the way to product-based evaluationâ€"a WAO statement. World Allergy Organization Journal, 2015, 8, 29.	3.5	70
85	Quality of Life in Duchenne Muscular Dystrophy: The Subjective Impact on Children and Parents. Journal of Child Neurology, 2011, 26, 707-713.	1.4	69
86	COVIDâ€19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 887-892.	5.7	69
87	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelinesâ€"Recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1058-1068.	5.7	67
88	ARIAâ€EAACI statement on severe allergic reactions to COVIDâ€19 vaccines â€“ An EAACIâ€ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1624-1628.	5.7	66
89	Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. Frontiers in Medicine, 2017, 4, 135.	2.6	65
90	Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 871-881.	5.6	65

#	Article	IF	Citations
91	Evidence of intercellular adhesion molecule-1 expression on nasal epithelial cells in acute rhinoconjunctivitis caused by pollen exposure. Journal of Allergy and Clinical Immunology, 1994, 94, 738-746.	2.9	64
92	World Allergy Organization Guidelines for Prevention of Allergy and Allergic Asthma. International Archives of Allergy and Immunology, 2004, 135, 83-92.	2.1	64
93	Enhancing Respiratory Medication Adherence: The Role of Health Care Professionals and Cost-Effectiveness Considerations. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 835-846.	3.8	64
94	Continuous Versus On Demand Treatment with Cetirizine for Allergic Rhinitis. Annals of Allergy, Asthma and Immunology, 1997, 79, 507-511.	1.0	62
95	Health-related quality of life assessment in young adults with seasonal allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 313-317.	5.7	61
96	Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. International Immunology, 2009, 21, 779-791.	4.0	61
97	Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients â€“ an observational, cross sectional study in four countries in Europe. Journal of Medical Economics, 2011, 14, 305-314.	2.1	61
98	Patient Perceptions of Allergic Rhinitis and Quality of Life. World Allergy Organization Journal, 2008, 1, 138-144.	3.5	60
99	The IgE repertoire in children and adolescents resolved at component level: A crossâ€sectional study. Pediatric Allergy and Immunology, 2012, 23, 433-440.	2.6	59
100	IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. Pulmonary Pharmacology and Therapeutics, 2017, 45, 95-100.	2.6	59
101	A Charter to Improve Patient Care in Severe Asthma. Advances in Therapy, 2018, 35, 1485-1496.	2.9	59
102	Drug Treatment of Allergic Conjunctivitis. Drugs, 1992, 43, 154-176.	10.9	58
103	Perturbations of natural killer cell regulatory functions in respiratory allergic diseases. Journal of Allergy and Clinical Immunology, 2008, 121, 479-485.	2.9	58
104	Asthma: personalized and precision medicine. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 51-58.	2.3	57
105	One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101836.	2.6	57
106	ARIAâ€EAACI statement on asthma and COVIDâ€19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
107	Pharmacokinetics of Der p 2 Allergen and Derived Monomeric Allergoid in Allergic Volunteers. International Archives of Allergy and Immunology, 2005, 138, 197-202.	2.1	56
108	Characteristics and treatment regimens across ERS SHARP severe asthma registries. European Respiratory Journal, 2020, 55, 1901163.	6.7	56

#	Article	IF	Citations
109	Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Âmonths. Clinical and Translational Allergy, 2017, 7, 6.	3.2	55
110	Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. Respiratory Medicine, 2020, 166, 105947.	2.9	55
111	Antihistaminic, Anti-Inflammatory, and Antiallergic Properties of the Nonsedating Second-Generation Antihistamine Desloratadine: a Review of the Evidence. World Allergy Organization Journal, 2011, 4, 47-53.	3.5	54
112	Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Annals of Allergy, Asthma and Immunology, 2008, 101, 304-310.	1.0	53
113	The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group. European Respiratory Journal, 2019, 54, 1901511.	6.7	53
114	Receptors for Immunoglobulins on Resting and Activated Human T Cells. Immunological Reviews, 1981, 56, 141-162.	6.0	52
115	Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 309-319.	1.4	52
116	<scp>ARIA</scp> pharmacy 2018 â€œAllergic rhinitis care pathways for community pharmacyâ€• Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	5.7	52
117	Treating Asthma as an Inflammatory Disease. Chest, 2006, 130, 21S-28S.	0.8	51
118	Efficacy of Desloratadine in Persistent Allergic Rhinitis â€“ A GA²LEN Study. International Archives of Allergy and Immunology, 2010, 153, 395-402.	2.1	51
119	Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2680-2688.e7.	3.8	50
120	Clara cell 16 protein in COPD sputum: A marker of small airways damage?. Respiratory Medicine, 2007, 101, 2119-2124.	2.9	49
121	Psychological aspects in asthma: do psychological factors affect asthma management?. Asthma Research and Practice, 2015, 1, 7.	2.4	49
122	Biomarkers and severe asthma: a critical appraisal. Clinical and Molecular Allergy, 2015, 13, 20.	1.8	49
123	Focus on Cat Allergen (Fel d 1): Immunological and Aerodynamic Characteristics, Modality of Airway Sensitization and Avoidance Strategies. International Archives of Allergy and Immunology, 2003, 132, 1-12.	2.1	48
124	An update on the asthma-rhinitis link. Current Opinion in Allergy and Clinical Immunology, 2004, 4, 177-183.	2.3	48
125	Bilastine: new insight into antihistamine treatment. Clinical and Molecular Allergy, 2015, 13, 1.	1.8	47
126	Effects of fexofenadine and other antihistamines on components of the allergic response. Journal of Allergy and Clinical Immunology, 2003, 112, S78-S82.	2.9	46

#	Article	IF	Citations
127	Bridging allergologic and botanical knowledge in seasonal allergy: a role for phenology. Annals of Allergy, Asthma and Immunology, 2010, 105, 223-227.	1.0	46
128	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
129	ASSUREâ€CSU: a realâ€world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. Clinical and Translational Allergy, 2015, 5, 29.	3.2	45
130	Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAIDâ€ERD: Results from two randomized placeboâ€controlled phase 3 trials. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1231-1244.	5.7	45
131	COVID-19 mortality rates in the European Union, Switzerland, and the UK: effect of timeliness, lockdown rigidity, and population density. Minerva Medica, 2020, 111, 308-314.	0.9	45
132	Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. Journal of the American Academy of Dermatology, 2003, 49, 714-716.	1.2	44
133	Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of Î±-SMA and NF-ÎºB. International Immunology, 2005, 17, 1473-1481.	4.0	44
134	Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due tograss pollen. Annals of Allergy, Asthma and Immunology, 2009, 102, 69-75.	1.0	44
135	Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respiratory Medicine, 2006, 100, 1706-1715.	2.9	43
136	Allergen Immunotherapy. Immunology and Allergy Clinics of North America, 2016, 36, 1-12.	1.9	43
137	The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: ÂÂGlobal Allergy and Asthma European Network (GA2LEN) article. Journal of Allergy and Clinical Immunology, 2011, 127, 49-56.e11.	2.9	42
138	Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma. BioMed Research International, 2018, 2018, 1-8.	1.9	42
139	Sex in Respiratory and Skin Allergies. Clinical Reviews in Allergy and Immunology, 2019, 56, 322-332.	6.5	42
140	Disease-modifying anti-asthmatic drugs. Lancet, The, 2022, 399, 1664-1668.	13.7	42
141	30 years of sublingual immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1107-1120.	5.7	41
142	Personalized Medicine in Allergy. Allergy, Asthma and Immunology Research, 2017, 9, 15.	2.9	40
143	Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and XolairÂ® In the Management of Asthma) study. Allergy, Asthma and Clinical Immunology, 2019, 15, 65.	2.0	39
144	Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 578-588.e2.	3.8	39

#	Article	IF	Citations
145	Allergen immunotherapy: The growing role of observational and randomized trial â€œRealâ€World Evidenceâ€• Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2663-2672.	5.7	39
146	Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial. Annals of Allergy, Asthma and Immunology, 2010, 105, 382-386.	1.0	38
147	Antibiotic Treatment of Severe Exacerbations of Chronic Obstructive Pulmonary Disease with Procalcitonin: A Randomized Noninferiority Trial. PLoS ONE, 2015, 10, e0118241.	2.5	38
148	The international survey on the management of allergic rhinitis by physicians and patients (ISMAR). World Allergy Organization Journal, 2015, 8, 10.	3.5	38
149	Therapeutic interventions in severe asthma. World Allergy Organization Journal, 2016, 9, 40.	3.5	38
150	Targeted therapy in severe asthma today: focus on immunoglobulin E. Drug Design, Development and Therapy, 2017, Volume 11, 1979-1987.	4.3	38
151	Omalizumab chronic spontaneous urticaria. Annals of Allergy, Asthma and Immunology, 2018, 121, 474-478.	1.0	38
152	International Severe Asthma Registry. Chest, 2020, 157, 805-814.	0.8	38
153	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1041-1052.	5.7	38
154	Pidotimod: the state of art. Clinical and Molecular Allergy, 2015, 13, 8.	1.8	37
155	World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Vitamin D. World Allergy Organization Journal, 2016, 9, 17.	3.5	37
156	Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?. Frontiers in Immunology, 2017, 8, 242.	4.8	37
157	Turkish Version of the Chronic Urticaria Quality of Life Questionnaire: Cultural Adaptation, Assessment of Reliability and Validity. Acta Dermato-Venereologica, 2012, 92, 419-425.	1.3	36
158	Local Side Effects of Sublingual and Oral Immunotherapy. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 13-21.	3.8	36
159	The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials. World Allergy Organization Journal, 2018, 11, 34.	3.5	36
160	Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Current Medical Research and Opinion, 2012, 28, 131-139.	1.9	35
161	Asthma from immune pathogenesis to precision medicine. Seminars in Immunology, 2019, 46, 101294.	5.6	35
162	Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 150-161.	5.7	35

#	Article	IF	Citations
163	Disability in COPD and its relationship to clinical and patient-reported outcomes. Current Medical Research and Opinion, 2011, 27, 981-986.	1.9	34
164	360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, pharmacists and patients. Clinical and Molecular Allergy, 2015, 13, 25.	1.8	34
165	Asthma mortality, inhaled steroids, and changing asthma therapy in Argentina (1990â€“1999). Respiratory Medicine, 2006, 100, 1431-1435.	2.9	33
166	Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. Current Medical Research and Opinion, 2008, 24, 2829-2839.	1.9	33
167	Evidences of efficacy of allergen immunotherapy in atopic dermatitis. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 427-433.	2.3	33
168	Latex immunotherapy: state of the art. Annals of Allergy, Asthma and Immunology, 2012, 109, 160-165.	1.0	33
169	Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 267-271.	2.3	33
170	Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. International Archives of Allergy and Immunology, 2021, 182, 324-338.	2.1	33
171	The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organization Journal, 2021, 14, 100533.	3.5	33
172	Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. Annals of Allergy, Asthma and Immunology, 2001, 86, 433-438.	1.0	32
173	New insights into airway remodelling in asthma and its possible modulation. Current Opinion in Allergy and Clinical Immunology, 2008, 8, 367-375.	2.3	32
174	Feasibility and validation of telespirometry in general practice: The Italian â€œAllianceâ€•study. Respiratory Medicine, 2009, 103, 1732-1737.	2.9	32
175	Allergenius, an expert system for the interpretation of allergen microarray results. World Allergy Organization Journal, 2014, 7, 15.	3.5	32
176	Validation of the Global Allergy and Asthma European Network (GA 2 LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber. Journal of Allergy and Clinical Immunology, 2017, 139, 1158-1166.	2.9	32
177	The Safety of Allergen Specific Sublingual Immunotherapy. Current Drug Safety, 2007, 2, 117-123.	0.6	31
178	Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI. Allergy, Asthma and Immunology Research, 2021, 13, 219.	2.9	31
179	Medical treatment reverses cytokine pattern in allergic and nonallergic chronic rhinosinusitis in asthmatic children. Pediatric Allergy and Immunology, 2003, 14, 238-241.	2.6	30
180	A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis. Clinical Therapeutics, 2005, 27, 979-992.	2.5	30

#	Article	IF	Citations
181	Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. Journal of Medical Economics, 2007, 10, 285-296.	2.1	30
182	Office spirometry can improve the diagnosis of obstructive airway disease in primary care setting. Respiratory Medicine, 2009, 103, 866-872.	2.9	30
183	Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 656-662.	2.3	30
184	Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. Clinical and Molecular Allergy, 2015, 13, 7.	1.8	30
185	Switching treatments in COPD: implications for costs and treatment adherence. International Journal of COPD, 2015, 10, 2601.	2.3	30
186	Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN). World Allergy Organization Journal, 2016, 9, 37.	3.5	30
187	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). World Allergy Organization Journal, 2020, 13, 100464.	3.5	30
188	Comparison of the Effects in the Nose and Skin of a Single Dose of Desloratadine and Levocetirizine over 24 Hours. International Archives of Allergy and Immunology, 2004, 135, 143-147.	2.1	29
189	An update on allergen immunotherapy and asthma. Current Opinion in Pulmonary Medicine, 2014, 20, 109-117.	2.6	29
190	Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma. Current Allergy and Asthma Reports, 2016, 16, 88.	5.3	29
191	Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps. Expert Review of Clinical Immunology, 2018, 14, 731-737.	3.0	29
192	Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661984127.	2.6	29
193	Circulating T-cell subsets in Graves' disease: Differences between patients with active disease and in remission after 131J-therapy. Clinical Immunology and Immunopathology, 1983, 28, 265-271.	2.0	28
194	Novel Anti-inflammatory Effects of the Inhaled Corticosteroid Fluticasone Propionate During Lung Myofibroblastic Differentiation. Journal of Immunology, 2001, 167, 5329-5337.	0.8	28
195	Sublingual immunotherapy: an update. Current Opinion in Allergy and Clinical Immunology, 2004, 4, 31-36.	2.3	28
196	Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Expert Opinion on Pharmacotherapy, 2015, 16, 913-928.	1.8	28
197	Adherence to asthma treatments. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 49-55.	2.3	28
198	Is allergic sensitization relevant in severe asthma? Which allergens may be culprits?. World Allergy Organization Journal, 2017, 10, 2.	3.5	28

#	Article	IF	Citations
199	The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research. European Respiratory Journal, 2018, 52, 1801671.	6.7	28
200	Strategies to reduce corticosteroid-related adverse events in asthma. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 61-67.	2.3	28
201	Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. Respiratory Medicine, 2020, 171, 106080.	2.9	28
202	Advanced forecasting of SARSâ€CoVâ€2â€related deaths in Italy, Germany, Spain, and New York State. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1813-1815.	5.7	28
203	Allergen-Specific Nasal Challenge: Response Kinetics of Clinical and Inflammatory Events to Rechallenge. International Archives of Allergy and Immunology, 1998, 115, 157-161.	2.1	27
204	When Allergic Rhinitis is not Only Allergic. American Journal of Rhinology and Allergy, 2009, 23, 312-315.	2.0	27
205	The Effect of Intranasal Corticosteroids on Asthma Control and Quality of Life in Allergic Rhinitis with Mild Asthma. Journal of Asthma, 2011, 48, 41-47.	1.7	27
206	Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Current Medical Research and Opinion, 2013, 29, 1539-1551.	1.9	27
207	Asthma and COPD: Interchangeable use of inhalers. A document of Italian Society of Allergy, Asthma and Clinical Immmunology (SIAAIC) & Italian Society of Respiratory Medicine (SIMeR). Pulmonary Pharmacology and Therapeutics, 2015, 34, 25-30.	2.6	27
208	Fatal asthma; is it still an epidemic?. World Allergy Organization Journal, 2016, 9, 42.	3.5	27
209	Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?. Expert Review of Respiratory Medicine, 2016, 10, 29-38.	2.5	27
210	Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms. Clinical and Molecular Allergy, 2017, 15, 2.	1.8	27
211	Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Therapeutic Advances in Respiratory Disease, 2017, 11, 40-45.	2.6	27
212	Human lung myofibroblasts as effectors of the inflammatory process: the common receptor Î³â€‰ chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF-Î±. European Journal of Immunology, 2002, 32, 2437-2449.	2.9	26
213	Sublingual immunotherapy: update 2006. Current Opinion in Allergy and Clinical Immunology, 2006, 6, 449-454.	2.3	26
214	Disease-modifying effect and economic implications ofÂsublingual immunotherapy. Journal of Allergy and Clinical Immunology, 2011, 127, 44-45.	2.9	26
215	Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy and Asthma Proceedings, 2012, 33, 450-458.	2.2	26
216	AIT (allergen immunotherapy): a model for the â€œprecision medicineâ€• Clinical and Molecular Allergy, 2015, 13, 24.	1.8	26

#	Article	IF	Citations
217	Human T-Lymphocyte Subpopulations in Hashimotoâ€™s Disease*. Journal of Clinical Endocrinology and Metabolism, 1981, 52, 553-556.	3.6	25
218	Underdiagnosis and Undertreatment of Asthma: A 9-Year Study of Italian Conscripts. International Archives of Allergy and Immunology, 2001, 125, 211-215.	2.1	25
219	CD40 on Adult Human Airway Epithelial Cells: Expression and Proinflammatory Effects. Journal of Immunology, 2004, 172, 3205-3214.	0.8	25
220	Immunotherapy: clinical trials â€“ optimal trial and clinical outcomes. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 561-566.	2.3	25
221	The added value of allergen microarray technique to the management of poly-sensitized allergic patients. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 434-439.	2.3	25
222	Guideline recommendations on the use of allergen immunotherapy in house dust mite allergy: Time for a change?. Journal of Allergy and Clinical Immunology, 2017, 140, 41-52.	2.9	25
223	Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study. World Allergy Organization Journal, 2018, 11, 33.	3.5	25
224	Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA). Italian Journal of Dermatology and Venereology, 2018, 153, 133-145.	0.2	25
225	Clinical and cytologic characteristics of allergic rhinitis in elderly patients. Annals of Allergy, Asthma and Immunology, 2012, 108, 141-144.	1.0	24
226	Sublingual immunotherapy for allergic rhinitis and conjunctivitis. Immunotherapy, 2013, 5, 257-264.	2.0	24
227	Component-resolved diagnosis in pediatric allergic rhinoconjunctivitis and asthma. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 446-451.	2.3	24
228	Seeking allergy when it hides: which are the best fitting tests?. World Allergy Organization Journal, 2013, 6, 11.	3.5	23
229	Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: A survey. Respiratory Medicine, 2013, 107, 361-367.	2.9	23
230	A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clinical and Translational Allergy, 2015, 5, 36.	3.2	23
231	The role of interleukin 5 in asthma. Expert Review of Clinical Immunology, 2016, 12, 903-905.	3.0	23
232	Local allergic rhinitis: entopy or spontaneous response?. World Allergy Organization Journal, 2016, 9, 39.	3.5	23
233	CD4+CD25highCD127- regulatory T-cells in COPD: smoke and drugs effect. World Allergy Organization Journal, 2016, 9, 5.	3.5	23
234	An academic allergy unit during COVID-19 pandemic in Italy. Journal of Allergy and Clinical Immunology, 2020, 146, 227.	2.9	23

#	Article	IF	Citations
235	Spices to Control COVID-19 Symptoms: Yes, but Not Onlyâ€¦. International Archives of Allergy and Immunology, 2021, 182, 489-495.	2.1	23
236	One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1791-1803.	3.8	23
237	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. European Journal of Immunology, 1999, 29, 499-511.	2.9	22
238	The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 7-13.	2.3	22
239	Pharmacotherapy of allergic rhinitis: current options and future perspectives. Expert Opinion on Pharmacotherapy, 2014, 15, 73-83.	1.8	22
240	Targeting Interleukin-5 or Interleukin-5RÎ±: Safety Considerations. Drug Safety, 2017, 40, 559-570.	3.2	22
241	Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1202-1216.e23.	3.8	22
242	The role of Pneumococcal vaccine. Pulmonary Pharmacology and Therapeutics, 2008, 21, 608-615.	2.6	21
243	Impact of Bariatric Surgery on Pulmonary Function and Nitric Oxide in Asthmatic and Non-Asthmatic Obese Patients. Journal of Asthma, 2011, 48, 553-557.	1.7	21
244	Sleep Apnea Risk in Subjects With Asthma With or Without Comorbid Rhinitis. Respiratory Care, 2014, 59, 1851-1856.	1.6	21
245	Biomarker discovery in asthma and COPD by proteomic approaches. Proteomics - Clinical Applications, 2014, 8, 901-915.	1.6	21
246	The patient with rhinitis in the pharmacy. A cross-sectional study in real life. Asthma Research and Practice, 2015, 1, 4.	2.4	21
247	Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model. Clinical and Translational Allergy, 2020, 10, 23.	3.2	21
248	Local Nasal Specific Immunotherapy for Allergic Rhinitis. Allergy, Asthma and Clinical Immunology, 2006, 2, 117.	2.0	20
249	Airway remodelling in children: when does it start?. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 196-200.	2.3	20
250	Pitfalls in Respiratory Allergy Management: Alexithymia and Its Impact on Patient-Reported Outcomes. Journal of Asthma, 2011, 48, 25-32.	1.7	20
251	The possible influence of the environment on respiratory allergy: a survey on immigrants to Italy. Annals of Allergy, Asthma and Immunology, 2011, 106, 407-411.	1.0	20
252	Asthma Management Failure: A Flaw in Physicians' Behavior or in Patients' Knowledge?. Journal of Asthma, 2011, 48, 266-274.	1.7	20

#	Article	IF	Citations
253	Beta₂-agonists for exercise-induced asthma. The Cochrane Library, 2013, , CD003564.	2.8	20
254	Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey. Respiratory Research, 2013, 14, 94.	3.6	20
255	Allergy training and immunotherapy in Latin America: results of a regional overview. Annals of Allergy, Asthma and Immunology, 2013, 111, 415-419.e1.	1.0	20
256	RHINASTHMAâ€Adolescents: a new quality of life tool for patients with respiratory allergy. Pediatric Allergy and Immunology, 2014, 25, 450-455.	2.6	20
257	Macrogol hypersensitivity reactions during cleansing preparation for colon endoscopy. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 353-354.	3.8	20
258	Molecular diagnosis and precision medicine in allergy management. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1705-1714.	2.3	20
259	Current insights in allergen immunotherapy. Annals of Allergy, Asthma and Immunology, 2018, 120, 152-154.	1.0	20
260	Real-life studies of biologics used in asthma patients: key differences and similarities to trials. Expert Review of Clinical Immunology, 2019, 15, 951-958.	3.0	20
261	Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis. Clinical and Translational Allergy, 2020, 10, 25.	3.2	20
262	Successful SARS-CoV-2 vaccine allergy risk-management: The experience of a large Italian University Hospital. World Allergy Organization Journal, 2021, 14, 100541.	3.5	20
263	Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells. Immunology Letters, 2013, 149, 62-67.	2.5	19
264	Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology and Therapeutics, 2015, 33, 75-80.	2.6	19
265	Patients with Asthma and Comorbid Allergic Rhinitis: Is Optimal Quality of Life Achievable in Real Life?. PLoS ONE, 2012, 7, e31178.	2.5	19
266	Oral and sublingual immunotherapy in paediatric patients. Current Opinion in Allergy and Clinical Immunology, 2003, 3, 139-145.	2.3	18
267	The Clinical Characteristics of Respiratory Allergy in Immigrants in Northern Italy. International Archives of Allergy and Immunology, 2008, 147, 231-234.	2.1	18
268	Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. World Allergy Organization Journal, 2010, 3, 216-219.	3.5	18
269	Emerging drugs for allergic conjunctivitis. Expert Opinion on Emerging Drugs, 2014, 19, 291-302.	2.4	18
270	The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes. Pulmonary Pharmacology and Therapeutics, 2014, 27, 109-113.	2.6	18

#	Article	IF	Citations
271	Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia. Clinical and Molecular Allergy, 2017, 15, 19.	1.8	18
272	Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. Journal of Asthma, 2022, 59, 2201-2217.	1.7	18
273	Allergen-Specific Sublingual Immunotherapy for Respiratory Allergy. BioDrugs, 2001, 15, 509-519.	4.6	17
274	New insights in allergen avoidance measures for mite and pet sensitized patients. A critical appraisal. Respiratory Medicine, 2005, 99, 1363-1376.	2.9	17
275	Allergen-specific immunotherapy in asthmatic children: from the basis to clinical applications. Expert Review of Vaccines, 2013, 12, 639-659.	4.4	17
276	Long-acting bronchodilators improve Health Related Quality of Life in patients with COPD. Respiratory Medicine, 2013, 107, 1465-1480.	2.9	17
277	Sublingual Immunotherapy: Recent Advances. Allergology International, 2013, 62, 415-423.	3.3	17
278	Randomized controlled trial of desloratadine for persistent allergic rhinitis: Correlations between symptom improvement and quality of life. Allergy and Asthma Proceedings, 2013, 34, 274-282.	2.2	17
279	New Therapies for Allergic Rhinitis. Current Allergy and Asthma Reports, 2014, 14, 422.	5.3	17
280	The relationship between allergen immunotherapy and omalizumab for treating asthma. Expert Review of Respiratory Medicine, 2015, 9, 129-134.	2.5	17
281	Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety. Expert Review of Clinical Immunology, 2015, 11, 233-245.	3.0	17
282	GenuairÂ® Usability Test: Results of a National Public Survey of the Elderly. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 367-371.	1.6	17
283	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASKâ€ir^{Â®} realâ€world data. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2699-2711.	5.7	17
284	Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy. Allergologia Et Immunopathologia, 2006, 34, 82-83.	1.7	16
285	Eligibility for treatment with omalizumab in Italy and Germany. Respiratory Medicine, 2014, 108, 50-56.	2.9	16
286	Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respiratory Medicine, 2016, 115, 7-12.	2.9	16
287	Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 121-131.	1.4	16
288	Plasma Galectin-3 and urine proteomics predict FEV1 improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study. World Allergy Organization Journal, 2020, 13, 100095.	3.5	16

#	Article	IF	Citations
289	Managing Allergic Rhinitis in the Pharmacy: An ARIA Guide for Implementation in Practice. Pharmacy (Basel, Switzerland), 2020, 8, 85.	1.6	16
290	Management of anaphylaxis due to COVIDâ€19 vaccines in the elderly. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2952-2964.	5.7	16
291	Functional involvement of the LFA-1/ICAM-1 adhesion system in the autologous mixed lymphocyte reaction. Cellular Immunology, 1990, 128, 362-369.	3.0	15
292	Molecular events in allergic inflammation: experimental models and possible modulation. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 25-30.	5.7	15
293	Quality of life and polysensitization in young men with intermittent asthma. Annals of Allergy, Asthma and Immunology, 2005, 94, 640-643.	1.0	15
294	Update on immunotherapy for the treatment of asthma. Current Opinion in Pulmonary Medicine, 2016, 22, 18-24.	2.6	15
295	SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis. Allergy and Asthma Proceedings, 2016, 37, 92-104.	2.2	15
296	Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab: an Italian perspective. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 453-459.	2.3	15
297	Patient-reported outcomes in asthma clinical trials. Current Opinion in Pulmonary Medicine, 2018, 24, 70-77.	2.6	15
298	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseasesâ€"Meeting Report (Part 2). Journal of Thoracic Disease, 2019, 11, 4072-4084.	1.4	15
299	Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. Pulmonary Pharmacology and Therapeutics, 2019, 54, 87-89.	2.6	15
300	Clinical developmentof an advanced intranasal delivery sistem of azelastine hydrochloride and fluticasone propionate. Drugs of Today, 2014, 50, 15.	1.1	15
301	Antihistamines in the Treatment of Bronchial Asthma. Present Knowledge and Future Perspectives. Pulmonary Pharmacology and Therapeutics, 2001, 14, 267-276.	2.6	14
302	Lack of neo-sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy. Clinical and Molecular Allergy, 2010, 8, 4.	1.8	14
303	A review of the use of fluticasone furoate since its launch. Expert Opinion on Pharmacotherapy, 2011, 12, 2107-2117.	1.8	14
304	The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial. Immunology Letters, 2014, 162, 185-193.	2.5	14
305	Potential benefit of omalizumab in respiratory diseases. Annals of Allergy, Asthma and Immunology, 2014, 113, 513-519.	1.0	14
306	The perception of allergen-specific immunotherapy among pediatricians in the primary care setting. Clinical and Molecular Allergy, 2015, 13, 15.	1.8	14

#	Article	IF	Citations
307	Sublingual immunotherapy: focus on tablets. Annals of Allergy, Asthma and Immunology, 2015, 115, 4-9.	1.0	14
308	Treatable traits in chronic rhinosinusitis with nasal polyps. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 373-378.	2.3	14
309	Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 113-120.	3.3	14
310	Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel Report. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2920-2936.e1.	3.8	14
311	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organization Journal, 2021, 14, 100509.	3.5	14
312	Effects of allergen immunotherapy in the MASKâ€air study: a proofâ€ofâ€concept analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3212-3214.	5.7	14
313	Management of Allergic Conjunctivitis. BioDrugs, 1996, 5, 374-391.	0.7	13
314	Minimal persistent inflammation may be controlled by cetirizine. Annals of Allergy, Asthma and Immunology, 1999, 83, 445-448.	1.0	13
315	Crossâ€sectional comparison of the characteristics of respiratory allergy in immigrants and Italian children. Pediatric Allergy and Immunology, 2014, 25, 473-480.	2.6	13
316	Rhinitis: adherence to treatment and new technologies. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 23-27.	2.3	13
317	Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 208-218.	3.8	13
318	New drugs in early-stage clinical trials for allergic rhinitis. Expert Opinion on Investigational Drugs, 2019, 28, 267-273.	4.1	13
319	Clinical presentation at the onset of COVID-19 and allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3587-3589.	3.8	13
320	Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3084-3095.	5.7	13
321	Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement. Journal of Personalized Medicine, 2022, 12, 846.	2.5	13
322	Biologics in severe asthma: the role of real-world evidence from registries. European Respiratory Review, 2022, 31, 210278.	7.1	13
323	Inhibition of autologous mixed lymphocyte reaction by aggregated IgG molecules. European Journal of Immunology, 1982, 12, 687-691.	2.9	12
324	Intraepithelial Î³/Î´-Positive T Lymphocytes and Intestinal Villous Atrophy. International Archives of Allergy and Immunology, 1996, 110, 233-237.	2.1	12

#	Article	IF	Citations
325	Single-Dose Oral Tolerance Test with Alternative Compounds for the Management of Adverse Reactions to Drugs. International Archives of Allergy and Immunology, 2002, 129, 242-247.	2.1	12
326	Clinical and therapeutic aspects of allergic asthma in adolescents. Pediatric Allergy and Immunology, 2003, 14, 453-457.	2.6	12
327	Sublingual and oral immunotherapy. Immunology and Allergy Clinics of North America, 2004, 24, 685-704.	1.9	12
328	New perspectives in the treatment of allergic rhinitis and asthma in children. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 201-206.	2.3	12
329	Sublingual Immunotherapy: Other Indications. Immunology and Allergy Clinics of North America, 2011, 31, 279-287.	1.9	12
330	100 Years of Immunotherapy: The Monaco Charter. International Archives of Allergy and Immunology, 2013, 160, 346-349.	2.1	12
331	Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases. Journal of Thoracic Disease, 2016, 8, E716-E725.	1.4	12
332	Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma. Expert Review of Clinical Immunology, 2016, 12, 805-815.	3.0	12
333	Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4353-4370.	3.8	12
334	Comorbid allergic rhinitis and asthma: important clinical considerations. Expert Review of Clinical Immunology, 2022, 18, 747-758.	3.0	12
335	Deficiency of the Autologous Mixed Lymphocyte Reaction in Patients with Autoimmune Thyroid Disease. International Archives of Allergy and Immunology, 1984, 73, 137-140.	2.1	11
336	Unconventional medicine: a risk of undertreatment of allergic patients. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 1117-1119.	5.7	11
337	Non-Injection Routes for Allergen Immunotherapy: Focus on Sublingual Immunotherapy. Inflammation and Allergy: Drug Targets, 2006, 5, 43-51.	1.8	11
338	Sublingual immunotherapy: where do we stand? Present and future. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 1-3.	2.3	11
339	Sublingual Immunotherapy for Allergic Respiratory Diseases: Efficacy and Safety. Immunology and Allergy Clinics of North America, 2011, 31, 265-277.	1.9	11
340	Immunotherapy in polysensitized patients: new chances for the allergists?. Annals of Allergy, Asthma and Immunology, 2012, 109, 392-394.	1.0	11
341	Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10. PLoS ONE, 2012, 7, e37980.	2.5	11
342	SIT: efficacy depends on product, not on route of application. Pediatric Allergy and Immunology, 2012, 23, 401-401.	2.6	11

#	Article	IF	Citations
343	Disability in Moderate Chronic Obstructive Pulmonary Disease: Prevalence, Burden and Assessment - Results from a Real-Life Study. Respiration, 2015, 89, 100-106.	2.6	11
344	Biosimilars in allergic diseases. Current Opinion in Allergy and Clinical Immunology, 2016, 16, 68-73.	2.3	11
345	Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. Pulmonary Pharmacology and Therapeutics, 2017, 44, 83-87.	2.6	11
346	The era of research collaborations: new models for working together. European Respiratory Journal, 2017, 49, 1601848.	6.7	11
347	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseasesâ€"Meeting Report (Part 1). Journal of Thoracic Disease, 2019, 11, 3633-3642.	1.4	11
348	Effect of an educational intervention delivered by pharmacists on adherence to treatment, disease control and lung function in patients with asthma. Respiratory Medicine, 2020, 174, 106199.	2.9	11
349	A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM). Journal of Asthma and Allergy, 2021, Volume 14, 1019-1031.	3.4	11
350	Implementation of the MASK-AirÂ® App for Rhinitis and Asthma in Older Adults: MASK@Puglia Pilot Study. International Archives of Allergy and Immunology, 2022, 183, 45-50.	2.1	11
351	Quality of Life in Respiratory Allergy. Allergy and Asthma Proceedings, 2001, 22, 177-181.	2.2	10
352	Advances in Allergen-Specific Immunotherapy. Current Drug Targets, 2009, 10, 1255-1262.	2.1	10
353	Catching allergy by a simple questionnaire. World Allergy Organization Journal, 2015, 8, 16.	3.5	10
354	Allergen immunotherapy in asthma; what is new?. Asthma Research and Practice, 2015, 1, 6.	2.4	10
355	Clinical Characteristics Associated with Conjunctival Inflammation in Allergic Rhinoconjunctivitis. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 387-391.e1.	3.8	10
356	The path to personalized medicine in asthma. Expert Review of Respiratory Medicine, 2016, 10, 957-965.	2.5	10
357	The role of the pharmacy in the management of bronchial asthma. Annals of Allergy, Asthma and Immunology, 2017, 118, 161-165.	1.0	10
358	Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis. Clinical and Translational Allergy, 2021, 11, e12033.	3.2	10
359	Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. European Respiratory Journal, 2021, 58, 2004605.	6.7	10
360	Local nasal immunotherapy for allergic rhinitis: A systematic review and metaâ€analysis. International Forum of Allergy and Rhinology, 2022, 12, 1503-1516.	2.8	10

#	Article	IF	Citations
361	Abnormalities of Circulating T Cell Subsets in Atopy: Influence of Specific Immunotherapy. International Archives of Allergy and Immunology, 1983, 71, 300-303.	2.1	9
362	The relationship between asthma control and quality-of-life impairment due to chronic cough: a real-life study. Annals of Allergy, Asthma and Immunology, 2008, 101, 370-374.	1.0	9
363	Using the Congestion Quantifier Seven-Item Test to assess change in patient symptoms and their impact. Allergy and Asthma Proceedings, 2008, 29, 295-303.	2.2	9
364	Molecular allergy diagnosis: we need to become more knowledgeable. Annals of Allergy, Asthma and Immunology, 2012, 108, 387.	1.0	9
365	Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA â€“ an observational, 2 phase, patient reported outcomes study. Clinical and Molecular Allergy, 2015, 13, 10.	1.8	9
366	A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. Therapeutic Delivery, 2015, 6, 653-659.	2.2	9
367	Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry. Expert Review of Respiratory Medicine, 2021, 15, 419-424.	2.5	9
368	Allergen immunotherapy in MASKâ€air users in realâ€life: Results of a Bayesian mixedâ€effects model. Clinical and Translational Allergy, 2022, 12, e12128.	3.2	9
369	Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis. Frontiers in Allergy, 2022, 3, .	2.8	9
370	Serum cytotoxic T lymphocyteâ€“associated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy. Journal of Allergy and Clinical Immunology, 2009, 123, 258-260.	2.9	8
371	Coping with asthma: Is the physician able to identify patient's behaviour?. Respiratory Medicine, 2012, 106, 1625-1630.	2.9	8
372	Public awareness on cystic fibrosis: results from a national pragmatic survey. European Respiratory Journal, 2015, 46, 264-267.	6.7	8
373	The safety of monoclonal antibodies in asthma. Expert Opinion on Drug Safety, 2016, 15, 1087-1095.	2.4	8
374	The management of asthma in the phenotype and biomarker era: The proposal of a new diagnostic-therapeutic model. Journal of Asthma, 2016, 53, 665-667.	1.7	8
375	Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients. Human Immunology, 2016, 77, 1172-1178.	2.4	8
376	A critical appraisal on AIT in childhood asthma. Clinical and Molecular Allergy, 2018, 16, 6.	1.8	8
377	Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry . Journal of Asthma and Allergy, 2020, Volume 13, 599-604.	3.4	8
378	3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. European Respiratory Journal, 2021, 58, 2102168.	6.7	8

#	Article	IF	Citations
379	Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center. Biomedicines, 2022, 10, 200.	3.2	8
380	WAO-ARIA consensus on chronic cough â€“ Part 1: Role of TRP channels in neurogenic inflammation of cough neuronal pathways. World Allergy Organization Journal, 2021, 14, 100617.	3.5	8
381	Comparison of rhinitis treatments using <scp>MASK</scp>â€airÂ® data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	5.7	8
382	A model of allergen-driven human airway contraction: Î²2 pathway dysfunction without cytokine involvement. Annals of Allergy, Asthma and Immunology, 2005, 94, 273-278.	1.0	7
383	Safety Profile of Sublingual Immunotherapy. Treatments in Respiratory Medicine, 2006, 5, 225-234.	1.4	7
384	New insights in sublingual immunotherapy. Current Allergy and Asthma Reports, 2006, 6, 407-412.	5.3	7
385	Sublingual immunotherapy for allergic rhinitis: an update. Current Opinion in Otolaryngology and Head and Neck Surgery, 2011, 19, 43-47.	1.8	7
386	Novelin silicotechnology in combination with microarrays: a state-of-the-art technology for allergy diagnosis and management?. Expert Review of Clinical Immunology, 2014, 10, 1559-1561.	3.0	7
387	The perception of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) among Italian general practitioners. Clinical and Molecular Allergy, 2015, 13, 4.	1.8	7
388	Escaping the trap of allergic rhinitis. Clinical and Molecular Allergy, 2015, 13, 17.	1.8	7
389	Umeclidinium for the treatment of uncontrolled asthma. Expert Opinion on Investigational Drugs, 2017, 26, 761-766.	4.1	7
390	Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from in vitro allergen-release data. Expert Review of Clinical Immunology, 2019, 15, 921-928.	3.0	7
391	Responders and nonresponders to pharmacotherapy and allergen immunotherapy. Human Vaccines and Immunotherapeutics, 2019, 15, 2896-2902.	3.3	7
392	Evolving phenotypes to endotypes: is precision medicine achievable in asthma?. Expert Review of Respiratory Medicine, 2020, 14, 163-172.	2.5	7
393	Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110425.	2.6	7
394	Real-life survey on severe asthma patients during COVID-19 lockdown in Italy. Expert Review of Respiratory Medicine, 2021, 15, 1057-1060.	2.5	7
395	Prospective Italian realâ€world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports. Clinical and Translational Allergy, 2021, 11, e12067.	3.2	7
396	T cell-mediated mechanisms in autoimmune thyroiditis. Immunologic Research, 1986, 5, 305-313.	2.9	6

#	Article	IF	Citations
397	Investigational drugs for allergic rhinitis. Expert Opinion on Investigational Drugs, 2010, 19, 93-103.	4.1	6
398	Considerations about the evaluation of the SLIT meta-analyses. Journal of Allergy and Clinical Immunology, 2010, 125, 509.	2.9	6
399	Persistent Allergic Rhinitis and the XPERT Study. World Allergy Organization Journal, 2011, 4, S32-S36.	3.5	6
400	Towards the Grade of Recommendations, Assessment, Development and Evaluation system. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 361-374.	2.3	6
401	History of the World Allergy Organization: Innovation in Continuity 2008-2009. World Allergy Organization Journal, 2011, 4, 188-192.	3.5	6
402	Persistent Allergic Rhinitis and the XPERT Study. World Allergy Organization Journal, 2011, 4, S32-S36.	3.5	6
403	Chronic Obstructive Pulmonary Disease Patient Well-Being and Its Relationship with Clinical and Patient-Reported Outcomes: A Real-Life Observational Study. Respiration, 2011, 82, 335-340.	2.6	6
404	Allergens and bacteria interaction in the induction of basophil activation. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 164-170.	2.3	6
405	Ranking in importance of allergen extract characteristics for sublingual immunotherapy by Italian specialists. Allergy and Asthma Proceedings, 2014, 35, 43-46.	2.2	6
406	The WEB-based Asthma Control: an intriguing connection or a dangerous hazard?. Asthma Research and Practice, 2015, 1, 15.	2.4	6
407	Clinically significant differences in patient-reported outcomes evaluations in chronic spontaneous urticaria. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 261-267.	2.3	6
408	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. Journal of Clinical Medicine, 2020, 9, 2397.	2.4	6
409	Nonsteroidal Antiallergic Treatments in Allergic Rhinitis. American Journal of Rhinology & Allergy, 2000, 14, 319-324.	2.2	5
410	Formoterol by Pressurized Metered-Dose Aerosol or Dry Powder on Airway Obstruction and Lung Hyperinflation in Partially Reversible COPD. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2011, 24, 235-243.	1.4	5
411	DRACMA one year after: Which changes have occurred in diagnosis and treatment of CMA in Italy?. Italian Journal of Pediatrics, 2011, 37, 53.	2.6	5
412	Asthma: developments in targeted therapy. Expert Review of Clinical Immunology, 2012, 8, 13-15.	3.0	5
413	The functional connection between oral allergy syndrome and united airways disease assessed by oral challenge. Annals of Allergy, Asthma and Immunology, 2012, 108, 30-33.	1.0	5
414	Will Sublingual Immunotherapy Offer Benefit for Asthma?. Current Allergy and Asthma Reports, 2013, 13, 571-579.	5.3	5

#	Article	IF	Citations
415	Choosing wisely in Allergology: a Slow Medicine approach to the discipline promoted by the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Clinical and Molecular Allergy, 2015, 13, 28.	1.8	5
416	Clinically relevant effect of rupatadine 20Âmg and 10Âmg in seasonal allergic rhinitis: a pooled responder analysis. Clinical and Translational Allergy, 2019, 9, 50.	3.2	5
417	T Cell Activation Surface Markers and Autologous Mixed Lymphocyte Reaction Do Not Differ in True and Pseudo Food Allergy. International Archives of Allergy and Immunology, 1987, 83, 193-197.	2.1	4
418	Do the current guidelines for asthma pharmacotherapy encourage over-treatment?. Expert Opinion on Pharmacotherapy, 2020, 21, 1283-1286.	1.8	4
419	Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study. Journal of Asthma, 2022, 59, 1908-1913.	1.7	4
420	Prevalence of familial link in patients affected by chronic rhinosinusitis with nasal polyposis. International Forum of Allergy and Rhinology, 2022, 12, 1562-1565.	2.8	4
421	Allergen-Specific Conjunctival Challenge in Asthma. International Archives of Allergy and Immunology, 1997, 112, 247-250.	2.1	3
422	The asthma-rhinitis association: Between the clinical hypothesis and the scientific theory. Current Allergy and Asthma Reports, 2003, 3, 191-193.	5.3	3
423	The Scope of Pharmacological and Clinical Effects of Modern Antihistamines, With a Special Focus on Rupatadine: Proceedings from a Satellite Symposium held at the 21st World Allergy Congress, Buenos Aires, December 8, 2009. World Allergy Organization Journal, 2010, 3, S1-S16.	3.5	3
424	Review of Desloratadine Data Using the ARIA Guidelines. World Allergy Organization Journal, 2012, 5, S6-S13.	3.5	3
425	Is Health-Related Quality of Life Associated with Upper and Lower Airway Inflammation in Asthmatics?. BioMed Research International, 2013, 2013, 1-7.	1.9	3
426	Year in review: allergen immunotherapy. Annals of Allergy, Asthma and Immunology, 2015, 114, 173-174.	1.0	3
427	A valid option for asthma control: Clinical evidence on efficacy and safety of fluticasone propionate/formoterol combination in a single inhaler. Pulmonary Pharmacology and Therapeutics, 2015, 34, 31-36.	2.6	3
428	Choose your outcomes: From the mean to the personalized assessment of outcomes in COPD. An exploratory pragmatic survey. European Journal of Internal Medicine, 2016, 34, 85-88.	2.2	3
429	Personalizing the approach to asthma treatment. Expert Review of Precision Medicine and Drug Development, 2018, 3, 299-304.	0.7	3
430	Rhinitis and Asthma Patient PerspectiveÂ(RAPP): Clinical Utility and Predictive Value. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 846-852.e1.	3.8	3
431	Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ?. Frontiers in Allergy, 2022, 3, 854080.	2.8	3
432	The effect of the COVID-19 pandemic on severe asthma care in Europe - will care change for good?. ERJ Open Research, 2022, 8, 00065-2022.	2.6	3

#	Article	IF	Citations
433	Antiallergic drugs and quality of life. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 437-445.	1.4	2
434	Levocetirizine in the treatment of allergic diseases. Expert Opinion on Pharmacotherapy, 2009, 10, 2367-2377.	1.8	2
435	Emerging sublingual immunotherapy drugs. Expert Opinion on Pharmacotherapy, 2010, 11, 2963-2972.	1.8	2
436	Review of Desloratadine Data Using the ARIA Guidelines. World Allergy Organization Journal, 2012, 5, S6-S13.	3.5	2
437	Cochrane Review: Sublingual immunotherapy for treating allergic conjunctivitis. Evidence-Based Child Health: A Cochrane Review Journal, 2012, 7, 1041-1154.	2.0	2
438	Microarray Immunodiagnostics for Aeroallergens. Current Allergy and Asthma Reports, 2019, 19, 10.	5.3	2
439	Overcoming Barriers to the Effective Management of Severe Asthma in Italy. Journal of Asthma and Allergy, 2021, Volume 14, 481-491.	3.4	2
440	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. European Journal of Immunology, 1999, 29, 499-511.	2.9	2
441	Impact of Urticaria: QOL and Performance. , 2010, , 33-36.		2
442	Glycoproteic nature of surface molecules of effector cells with lymphokine-activated killer (LAK) activity. Evidence that T11, T8 or T3 molecules are not involved in tumor-cell lysis by LAK effector T cells. International Journal of Cancer, 1987, 39, 703-707.	5.1	1
443	Sublingual immunotherapy: what lessons can we draw from recent studies?. Revue Francaise D'allergologie Et D'immunologie Clinique, 2004, 44, 584-589.	0.1	1
444	Important Factors to Consider for Patients with Community-Acquired Pneumonia. Clinical Infectious Diseases, 2005, 40, 1374-1375.	5.8	1
445	Freedom to enjoy life - the ultimate goal in allergy management. Clinical and Experimental Allergy Reviews, 2006, 6, 15-19.	0.3	1
446	Freedom to enjoy life - the ultimate goal in allergy management. Clinical and Experimental Allergy Reviews, 2006, 6, 15-19.	0.3	1
447	Targeted therapy for allergic asthma: predicting and evaluating response to omalizumab. Expert Review of Clinical Immunology, 2007, 3, 463-467.	3.0	1
448	Worldwide differences on the concept of control of asthma. Therapeutic Advances in Respiratory Disease, 2008, 2, 3-5.	2.6	1
449	Specific immunotherapy with allergens: an important tool in the treatment of the allergic diseases. JDDG - Journal of the German Society of Dermatology, 2012, 10, 879-886.	0.8	1
450	European medicines agency guideline for biological medicinal products: a further step for a safe use of biosimilars. Clinical and Molecular Allergy, 2015, 13, 3.	1.8	1

#	Article	IF	Citations
451	MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis. Expert Opinion on Biological Therapy, 2016, 16, 1435-1441.	3.1	1
452	Appropriateness in allergic respiratory diseases health care in Italy: definitions and organizational aspects. Clinical and Molecular Allergy, 2016, 14, 5.	1.8	1
453	The year in review: The best of 2016 in the Annals. Annals of Allergy, Asthma and Immunology, 2017, 118, 4-9.	1.0	1
454	Antihistamines in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 1989, 44, 114-116.	5.7	1
455	New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases. Current Pharmaceutical Biotechnology, 2017, 18, 378-383.	1.6	1
456	T-LYMPHOCYTE ACTIVATION AND ALLERGY. Lancet, The, 1988, 332, 399.	13.7	0
457	Does allergic rhinosinusitis exist?. Revue Francaise D'allergologie Et D'immunologie Clinique, 2003, 43, 236-239.	0.1	0
458	Is Sublingual Immunotherapy the Final Answer? Implications for the Allergist. World Allergy Organization Journal, 2008, 1, 70-72.	3.5	0
459	Preface - a new section for our Journal - â€˜Perspectivesâ€™. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 378.	2.3	0
460	Section 3. A Discussion of Flexible Dosing and Patient-Centered Therapy. World Allergy Organization Journal, 2010, 3, 31-37.	3.5	0
461	Letter to the Editor. Current Medical Research and Opinion, 2014, 30, 207-209.	1.9	0
462	One-Year Evolution of Symptoms and Health Status of the COPD Multi-Dimensional Phenotypes: Results from the Follow-Up of the STORICO Observational Study. International Journal of COPD, 2021, Volume 16, 1007-1020.	2.3	0
463	Prof. Mario SÃ¡nchez Borges: An enduring legacy and a life wellâ€lived. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1948-1949.	5.7	0
464	Clinical Evolution and Quality of Life in Clinically Based COPD Chronic Bronchitic and Emphysematous Phenotypes: Results from the 1-Year Follow-Up of the STORICO Italian Observational Study. International Journal of COPD, 2021, Volume 16, 2133-2148.	2.3	0
465	COVID-19 Pandemicâ€"Allergen-specific Immunotherapy Positioning in Respiratory Allergy. US Respiratory & Pulmonary Diseases, 2020, 5, 10.	0.2	0